Weekly Digest – November 2026 Weekly Digest – November 2026 30 October 2026: NMPA grants Priority Review to Hengrui’s Trastuzumab Rezetecan NDA for 1L HER2-positive Breast cancer Hengrui Medicine’s subsidiary, Suzhou Shengdiya, received NMPA acceptance and Priority Review for SHR-A1811, a HER2-targeted […]